Companies: 10,795·Total market cap: $144.5T
Alector, Inc.

Alector, Inc.

ALECNASDAQHealthcare● Active
$1.64
+$0.01(+0.31%)
Market Cap$182081000
P/E Ratio
52W High$3.4
52W Low$1.09

Alector, Inc. (ALEC) Stock Ownership

Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.

SEC 13F · FMP · ALEC · as of Sep 30, 2025

Ownership Breakdown

Institutions 67.34%
Insiders 29.32%
Public 3.34%

157

Institutional Holders

▲ 20 vs Q2

$221.31M

Total Inst. Value

▲ $122.59M vs Q2

111.03M

Shares Outstanding

freeFloat 70.68%

74.77M

13F Shares Held

▲ 4.26M vs Q2

Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.

Top Institutional Holders

ALEC largest shareholders · institutional ownership

Q3 2025 · SEC 13F

Showing top 10 holders

HolderShares% OwnedWeightValueReportedChange

FMR LLC

biological products, (no diagnostic substances)

15.18M15.13%

15.13%

$44.94BNov 13, 2025 183.0K

BLACKROCK, INC.

biological products, (no diagnostic substances)

7.20M7.17%

7.17%

$21.31BNov 12, 2025 775.6K

RTW INVESTMENTS, LP

biological products, (no diagnostic substances)

6.99M6.96%

6.96%

$20.69BNov 14, 2025NEW

VANGUARD GROUP INC

biological products, (no diagnostic substances)

6.03M6.01%

6.01%

$17.86BNov 7, 2025 47.0K

MERCK & CO., INC.

biological products, (no diagnostic substances)

3.55M3.53%

3.53%

$10.50BNov 12, 2025— held

ACADIAN ASSET MANAGEMENT LLC

biological products, (no diagnostic substances)

2.37M2.36%

2.36%

$7.02BNov 13, 2025 202.6K

PRICE T ROWE ASSOCIATES INC /MD/

biological products, (no diagnostic substances)

2.19M2.18%

2.18%

$6.47BNov 14, 2025 2.69M

GEODE CAPITAL MANAGEMENT, LLC

biological products, (no diagnostic substances)

1.86M1.85%

1.85%

$5.51BNov 12, 2025 120.8K

STATE STREET CORP

biological products, (no diagnostic substances)

1.73M1.73%

1.73%

$5.13BNov 14, 2025 24.8K

EVERSEPT PARTNERS, LP

biological products, (no diagnostic substances)

1.49M1.48%

1.48%

$4.41BNov 14, 2025 497.3K

Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).

Institutional Activity

Q3 2025 vs prior quarter

Q3 2025

Net institutional sentimentBullish — more buying than selling

25

Increased

+4.89M shares

3

New Positions

first time holders

16

Decreased

−5.72M shares

0

Sold Out

fully exited

Net shares change (top 50)

829.8K

+4.89M / −5.72M

Net new holders

+12

3 new / 0 exited

Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).

Insider Buying vs Selling

ALEC insider trading · insider activity

Source: SEC Form 4

Buy 0%Active transactions only100% Sell

Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.

0

Buy transactions

1

Sell transactions

0.00

Buy/Sell ratio

$0M

Total disposed

Recent Insider Transactions

Showing 10 most recent · Common Stock only

Name · RoleDateTypeSharesPriceValueAfter Trans.Filing

SCHELLER RICHARD H

director

Jun 1, 2026Award10,833106.2KForm 4 ↗

Wong-Sarad Grace

Principal Accounting Officer

Apr 16, 2026Sale1,820$2.65$4.8K104.6KForm 4 ↗

Rosenthal Arnon

Chief Executive Officer

Mar 13, 2026Award116,2462.45MForm 4 ↗

Berkley Neil Lindsay

CFO & Chief Business Officer

Mar 15, 2026Award54,600399.3KForm 4 ↗

Wong-Sarad Grace

Principal Accounting Officer

Mar 10, 2026Sale1,000$2.65$2.6K106.5KForm 4 ↗

Wong-Sarad Grace

Principal Accounting Officer

Mar 3, 2026Sale3,367$2.08$7.0K107.5KForm 4 ↗

Wong-Sarad Grace

Principal Accounting Officer

Mar 2, 2026Sale8,071$2.12$17.1K110.8KForm 4 ↗

Rosenthal Arnon

Chief Executive Officer

Mar 2, 2026Sale81,864$2.12$173.8K2.34MForm 4 ↗

Berkley Neil Lindsay

CFO & Chief Business Officer

Mar 2, 2026Sale29,649$2.12$63.0K344.7KForm 4 ↗

Wong-Sarad Grace

Principal Accounting Officer

Feb 26, 2026Sale4,079$2.50$10.2K118.9KForm 4 ↗

Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.

About institutional & insider ownership

Alector, Inc. (ALEC) is primarily owned by institutional investors, who hold approximately 67.3% of total shares outstanding. Company insiders own approximately 29.32%, while retail and public investors account for the remaining 3.34%.

The largest institutional shareholder of Alector, Inc. is FMR LLC, holding approximately 15.18 million shares — equal to 15.13% of outstanding shares — as of September 30, 2025.

A total of 157 institutional investors currently hold ALEC stock, with a combined institutional value of approximately $221,307,345 as of the most recent 13F filing period.

Frequently asked questions

ALEC ownership

Alector, Inc. (ALEC) is primarily owned by institutional investors, who hold approximately 67.3% of shares. The largest shareholder is FMR LLC with a 15.13% stake. Company insiders hold 29.32%. Data sourced from SEC Form 13F as of September 30, 2025.

who owns ALEC stockALEC ownership structureSEC Form 13F institutional holdingsALEC float vs institutions
Source: FMP · SEC Form 13F · SEC Form 4As of September 30, 2025